Paul J. Rowe

1.8k total citations · 1 hit paper
79 papers, 875 citations indexed

About

Paul J. Rowe is a scholar working on Physiology, Immunology and Surgery. According to data from OpenAlex, Paul J. Rowe has authored 79 papers receiving a total of 875 indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Physiology, 33 papers in Immunology and 30 papers in Surgery. Recurrent topics in Paul J. Rowe's work include Asthma and respiratory diseases (64 papers), IL-33, ST2, and ILC Pathways (32 papers) and Eosinophilic Esophagitis (26 papers). Paul J. Rowe is often cited by papers focused on Asthma and respiratory diseases (64 papers), IL-33, ST2, and ILC Pathways (32 papers) and Eosinophilic Esophagitis (26 papers). Paul J. Rowe collaborates with scholars based in United States, France and United Kingdom. Paul J. Rowe's co-authors include Yamo Deniz, Juby A. Jacob‐Nara, William W. Busse, Klaus F. Rabe, Amr Radwan, Benjamin Ortiz, Mario Castro, Nadia Daizadeh, Marcella Ruddy and Asif Khan and has published in prestigious journals such as SHILAP Revista de lepidopterología, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Paul J. Rowe

72 papers receiving 857 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis

2022 146 citations Michael E. Wechsler, Amr Radwan et al. The Journal of Allergy and Clinical Immunology In Practice profile →

Peers

Paul J. Rowe

PHYSI

PRM

OTORH

SURGE

Juby A. Jacob‐Nara United States

Amr Radwan United States

Yanping Wu United States

M Gilson United Kingdom

Jantina C. de Groot Netherlands

K. Surrey United Kingdom

S. Hedgecock United Kingdom

Kęstutis Malakauskas Lithuania

Joachim Veith United States

S Conticello Italy

Juby A. Jacob‐Nara United States

Paul J. Rowe

548 ×0.9

PHYSI

246 ×0.7

PRM

327 ×1.2

240 ×1.2

OTORH

191 ×1.0

SURGE

Citations per year, relative to Paul J. Rowe Paul J. Rowe (= 1×) peers Juby A. Jacob‐Nara

Countries citing papers authored by Paul J. Rowe

Since Specialization

Citations

This map shows the geographic impact of Paul J. Rowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul J. Rowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul J. Rowe more than expected).

Fields of papers citing papers by Paul J. Rowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul J. Rowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul J. Rowe. The network helps show where Paul J. Rowe may publish in the future.

Co-authorship network of co-authors of Paul J. Rowe

This figure shows the co-authorship network connecting the top 25 collaborators of Paul J. Rowe. A scholar is included among the top collaborators of Paul J. Rowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul J. Rowe. Paul J. Rowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Porsbjerg, Celeste, Eleanor M. Dunican, Njira Lugogo, et al.. (2025). Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial. American Journal of Respiratory and Critical Care Medicine. 212(2). 241–252.

Celli, Bartolomé R., Klaus F. Rabe, Maarten van den Berge, et al.. (2025). Current Smoker: A Clinical Chronic Obstructive Pulmonary Disease Phenotype Affecting Disease Progression and Response to Therapy. American Journal of Respiratory and Critical Care Medicine. 211(5). 729–736. 5 indexed citations

Guilbert, Theresa W., Kevin R. Murphy, Eckard Hamelmann, et al.. (2024). Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study. Journal of Asthma and Allergy. Volume 17. 81–87. 2 indexed citations

Fokkens, Wytske J., Claus Bachert, Claire Hopkins, et al.. (2024). Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of gender: results from the SINUS‐52 trial. Clinical & Translational Immunology. 13(6). e1511–e1511. 2 indexed citations

Phipatanakul, Wanda, Christian Vogelberg, Leonard B. Bacharier, et al.. (2024). Dupilumab 200 mg was efficacious in children (6–11 years) with moderate‐to‐severe asthma for up to 2 years: EXCURSION open‐label extension study. Pediatric Pulmonology. 59(11). 2976–2983. 2 indexed citations

Bachert, Claus, Asif Khan, Wytske J. Fokkens, et al.. (2024). Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP. Journal of Allergy and Clinical Immunology. 154(6). 1442–1449. 3 indexed citations

Lane, Andrew P., Joaquim Mullol, Claire Hopkins, et al.. (2024). Dupilumab improves sense of smell and clinical outcomes in patients with severe chronic rhinosinusitis with nasal polyps with anosmia. Current Medical Research and Opinion. 41(1). 53–59. 1 indexed citations

Busse, William W., Ian Pavord, Michael E. Wechsler, et al.. (2024). Stability of Fractional Exhaled Nitric Oxide and Its Relationship With Exacerbation in Patients Aged 6 Years or Older With Uncontrolled, Moderate-to-Severe Asthma. CHEST Journal. 167(6). 1541–1546.

Rabe, Klaus F., Ian Pavord, William W. Busse, et al.. (2023). Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status. Allergy. 78(8). 2148–2156. 6 indexed citations

10.

Hopkins, Claire, Joaquim Mullol, Asif Khan, et al.. (2023). Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps. Otolaryngology. 170(4). 1173–1182. 4 indexed citations

11.

Pavord, Ian, Arnaud Bourdin, Alberto Papi, et al.. (2023). Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose. Allergy. 78(11). 2921–2932. 6 indexed citations

12.

Domingo, Christian, Klaus F. Rabe, David Price, et al.. (2023). Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose. ERJ Open Research. 9(6). 56–2023. 4 indexed citations

13.

Papadopoulos, Nikolaos G., Stanley J. Szefler, Leonard B. Bacharier, et al.. (2023). Assessment of dupilumab in children with moderate‐to‐severe type 2 asthma with or without evidence of allergic asthma. Allergy. 78(8). 2157–2167. 16 indexed citations

14.

Máspero, Jorge, Asif Khan, Carl Philpott, et al.. (2023). Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial. Journal of Asthma and Allergy. Volume 16. 323–332. 9 indexed citations

15.

Corren, Jonathan, David J. Jackson, Thomas B. Casale, et al.. (2023). Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization. Journal of Asthma and Allergy. Volume 16. 249–260. 4 indexed citations

16.

Corren, Jonathan, Nicola A. Hanania, William W. Busse, et al.. (2023). Efficacy of dupilumab in patients with uncontrolled, moderate‐to‐severe asthma with fungal sensitization. Clinical & Experimental Allergy. 53(10). 1020–1030. 3 indexed citations

17.

Hanania, Nicola A., Mario Castro, Eric D. Bateman, et al.. (2022). Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction. Annals of Allergy Asthma & Immunology. 130(2). 206–214.e2. 8 indexed citations

18.

Tohda, Yuji, Yoichi Nakamura, Takao Fujisawa, et al.. (2022). Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study. Allergology International. 72(1). 89–99. 5 indexed citations

19.

Pavord, Ian, William W. Busse, Christopher E. Brightling, et al.. (2022). Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design. ERJ Open Research. 9(2). 417–2022. 6 indexed citations

20.

Domingo, Christian, Jorge Máspero, Mario Castro, et al.. (2022). Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. The Journal of Allergy and Clinical Immunology In Practice. 10(7). 1835–1843. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact